EP0322094A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
N-terminal fragments of human serum albumin
Assignee: Albumedix Ltd
•
Filing: 1988-10-25
•
Granted: —
•
Expires: 2008-10-25
Abstract
Abstract Polypeptides corresponding to mature human serum albumin residues 1 to n, where n is between 369 and 419 inclusive, are useful as substitutes for albumin in the treatment of burns and shock in humans, the clearances of undesirable compounds, (such as bilirubin) from human blood, in laboratory growth media and in HSA assays. HSA (1-389) is particularly preferred, although not novel per se . The polypeptides may be produced by recombinant DNA techniques, especially in yeast.
Inventors
- 👤 David James Ballance
- 👤 Edward Hinchliffe
- 👤 Michael John Geisow
- 👤 Peter James Senior
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-10-26 07:52
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/76; C07K14/765; A; A61; A61P; A61P11/00; A61P17/00; A61P43/00; A61P7/00; A61P9/00; A61K; A61K38/00
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
29 words
A polypeptide comprising the N-terminal portion of mature human serum albumin up to amino acid residue n, where n is 369 to 419, but not 387, and variants thereof.
Claim 2
Dependent Claim
29 words
A polypeptide comprising the N-terminal portion of mature human serum albumin up to amino acid residue n, where n is 369 to 419, but not 387, and variants thereof.
Claim 3
Dependent Claim
30 words
A polypeptide according to Claim 1 wherein the polypeptide is selected from the group consisting of HSA (1-373), HSA (1-388), HSA (1-389), HSA (1-390) and HSA (1-407) and variants thereof.
Claim 4
Dependent Claim
18 words
A pharmaceutical composition comprising a polypeptide according to Claim 1 or 2 except that n may be 387.
Claim 5
Dependent Claim
16 words
A composition according to Claim 3 wherein the polypeptide is HSA (1-387) or a variant thereof.
Claim 6
Dependent Claim
61 words
A nucleotide sequence encoding a polypeptide comprising the N-terminal portion of mature human serum albumin up to amino acid residue n, where n is 309 to 419, and polypeptide variants thereof, the nucleotide sequence not being linked at its 3′ end to a further sequence encoding the C-terminal portion of mature human serum albumin from amino acid residue n+1 to 585.
Claim 7
Dependent Claim
61 words
A nucleotide sequence encoding a polypeptide comprising the N-terminal portion of mature human serum albumin up to amino acid residue n, where n is 309 to 419, and polypeptide variants thereof, the nucleotide sequence not being linked at its 3′ end to a further sequence encoding the C-terminal portion of mature human serum albumin from amino acid residue n+1 to 585.
Claim 8
Dependent Claim
11 words
A nucleotide sequence according to Claim 5 wherein n is 387.
Claim 9
Dependent Claim
39 words
A nucleotide sequence according to Claim 5 or 6 linked at its 5′ end to a further nucleotide sequence encoding a peptide corresponding to the pro-, pre-, or pre-pro- position of HSA, a methionine residue, or another leader sequence.
Claim 10
Dependent Claim
37 words
An expression vector suitable for transformation of and expression in a selected host, the vector comprising a nucleotide sequence according to any one of Claims 6 and 8 and the said nucleotide sequence being a DNA sequence.
Claim 11
Dependent Claim
11 words
A host organism transformed with a vector according to Claim 8.
Claim 12
Dependent Claim
12 words
A host organism according to Claim 9 which is Saccharomyces cerevisiae .
Claim 13
Dependent Claim
34 words
A process for the production of a polypeptide comprising the culture under suitable conditions of a host microorganism according to Claim 9 or 10, the said polypeptide being encoded by the said nucleotide sequence.
Claim 14
Dependent Claim
21 words
A laboratory medium for the growth of microorganisms comprising a polypeptide according to Claim 1, except that n may be 387.
Claim 15
Dependent Claim
10 words
A medium according to Claim 12 wherein n is 387.
References Cited (Backward Citations)
EP0073646A2
Cited
EP0201239A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.